DURECT Corporation (NASDAQ: DRRX) shares fell 31.8% to $1.16, after the company reported that its licensee Pain Therapeutics has received a complete response letter from the FDA for REMOXY. Share volume was 9.1 million, running away from an all-day average of 695,000
